UK Veterinary M&A Landscape in 2026

UK Veterinary M&A Trends and Market Structure

The UK veterinary market has undergone a decade of rapid consolidation, but M&A dynamics have now shifted materially following sustained regulatory intervention.

Between 2013 and 2023, corporate ownership rose from c.10% to almost 60% of UK practices, driven by private equity-backed roll-up strategies across the so-called “Big 6” groups. This consolidation prompted increasing scrutiny from the Competition and Markets Authority, which intervened in a series of completed transactions between 2021 and 2023, frequently requiring divestments to resolve local competition concerns.

While no formal ban was imposed, the practical effect has been a clear slowdown in acquisition activity from the largest consolidators. Transactions became slower, more conditional, and exposed to execution risk, effectively sidelining the Big 6 from further aggressive UK buy-and-build strategies.

The CMA’s final market investigation, published in March 2026, reinforces this shift. The regulator concluded that the market was not working well for consumers, highlighting limited price transparency, weak competition in local markets, and evidence of price increases following acquisitions.

Importantly, the CMA stopped short of structural remedies. There are no ownership caps or forced break-ups. Instead, the focus is on transparency and consumer empowerment, including mandatory price disclosure, ownership visibility, prescription fee caps, and improved comparability tools.

This is a critical nuance. The buy-and-build model is not prohibited, but it is fundamentally reshaped. Value creation through opaque post-acquisition price increases becomes far more difficult, while deal execution risk for large consolidators remains elevated due to ongoing merger scrutiny.

As a result, the acquirer landscape has narrowed. With the Big 6 largely constrained, activity has shifted towards smaller, private equity-backed platforms operating below the CMA’s radar.

The two most active buyers are Kin Vet Community and VetThing. Kin Vet, backed by Perwyn, has built a 20+ site platform since 2023 through steady bolt-on acquisitions. VetThing, the UK arm of Vetopia backed by Axcel, entered in late 2025 and is pursuing a similar expansion strategy with a differentiated, clinician-led ownership model.

Overall, the market remains investable but more disciplined. Consolidation will continue, but at a slower pace and with a greater emphasis on operational quality, clinician retention and transparent pricing, rather than financial engineering.